5th Jun 2013 07:00
FOR IMMEDIATE RELEASE | 5 JUNE 2013 |
NOTIFICATION OF AVIVA'S MAJOR INTEREST IN SHARES
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to confirm that its long standing shareholder Aviva plc ("Aviva") and its subsidiaries has notified the Company that it has recently increased its shareholding in ImmuPharma Ordinary Shares to 4,388,986 representing a 5.38% shareholding in the Company.
The full TR1 form is shown at the end of this announcement.
Commenting on the announcement, Richard Warr, Chairman said: "We are pleased to record that Aviva has again demonstrated its support for ImmuPharma, its assets and long term investment profile."
For further information please see the Group's web site, www.immupharma.com, or contact:
ImmuPharma PLC (www.immupharma.com) | |
Richard Warr, Chairman | +44 20 7152 4080 |
Dimitri Dimitriou, Chief Executive Officer | +44 20 7152 4080 |
Lisa Baderoon, Head of Investor Relations | +44 7721 413 496 |
Panmure Gordon | +44 20 7886 2500 |
Hugh Morgan, Fred Walsh, Hannah Woodley |
Notes to Editors
ImmuPharma
ImmuPharma is focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents. The Company's most advanced drug candidate, LupuzorTM a potential blockbuster drug for Lupus, a chronic autoimmune disease has recently received the approval from the US FDA to enter phase III with a Special Protocol Assessment and "Fast Track" designation. The Company's second potential blockbuster compound in cancer "IPP-204106" is completing a new Phase I/ II clinical trial with the next generation of "polyplexed Nucant". ImmuPharma was founded and is led by a commercially focused Board and management team with extensive experience.
Recently ImmuPharma announced that it had secured a £50 million, five year Equity Financing Facility ("EFF") with Darwin Strategic Limited ("Darwin"), a majority owned subsidiary of Henderson Global Investors' Volantis Capital ("Henderson Volantis") to fund ImmuPharma's late stage Lupuzor compound.
For more information on ImmuPharma please go to: www.immupharma.com.
For filings with the FSA include the annex | |
For filings with issuer exclude the annex | |
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES | |
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii | Immupharma plc | ||||
2. Reason for the notification (please tick the appropriate box or boxes): | |||||
An acquisition or disposal of voting rights | √ | ||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | |||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | |||||
An event changing the breakdown of voting rights | |||||
Other (please specify): | |||||
3. Full name of person(s) subject to thenotification obligation: iii | Aviva plc & its subsidiaries | ||||
4. Full name of shareholder(s) (if different from 3.):iv | Registered Holder:
BNY Norwich Union Nominees Limited 352,153*
Chase (GA Group) Nominees Limited 2,792,276*
Chase Nominees Limited 233,259*
*denotes direct interest
Chase (GA Group) Nominees Limited 351,098
Chase Nominees Limited 253,918
Vidacos Nominees Limited 406,282
| ||||
5. Date of the transaction and date onwhich the threshold is crossed orreached: v | 31 May 2013 | ||||
6. Date on which issuer notified: | 03 June 2013 | ||||
7. Threshold(s) that is/are crossed orreached: vi, vii | 3% to 4% change at Direct Interest Level and | ||||
8. Notified details: | |||||||||||
A: Voting rights attached to shares viii, ix | |||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | |||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights x | |||||||
Direct | Direct xi | Indirect xii | Direct | Indirect | |||||||
Ordinary Shares
GB0033711010 | 2,471,621 | 2,471,621 | 4,388,986 | 3,377,688 |
1,011,298 | 4.14% | 1.24% | ||||
| |||||||||||
B: Qualifying Financial Instruments | |||||||||||
Resulting situation after the triggering transaction | |||||||||||
Type of financialinstrument | Expirationdate xiii | Exercise/Conversion Period xiv | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | |||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | ||||||
Resulting situation after the triggering transaction | ||||||
Type of financialinstrument | Exercise price | Expiration date xvii | Exercise/Conversion period xviii | Number of voting rights instrument refers to
| % of voting rights xix, xx
| |
| Nominal | Delta | ||||
Total (A+B+C) | |
Number of voting rights | Percentage of voting rights |
4,388,986 | 5.38% |
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi | ||
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-
Aviva Investors Global Services Limited: ·; Aviva plc (Parent Company) ·; Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) ·; Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) ·; Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
| ||
Proxy Voting: | ||
10. Name of the proxy holder: | See Section 4 | |
11. Number of voting rights proxy holder will ceaseto hold: | ||
12. Date on which proxy holder will cease to holdvoting rights: | ||
13. Additional information: | Figures are based the total number of voting rights of 81,532,463. | |
14. Contact name: | Tracy Weimar, ImmuPharma plc | |
15. Contact telephone number: | 020 7152 4080 | |
Related Shares:
AvivaImmupharma